{"status": "ok", "totalResults": 813, "articles": [{"source": {"id": "mashable", "name": "Mashable"}, "author": "Ray White", "title": "Health innovation where it's needed most with Pfizer's Nanette Cocero", "description": "Pfizer Regional Director for Emerging Markets, Nanette Cocero, speaks to the Social Good Summit audience about bringing high quality healthcare to the 5.5 billion people living in emerging markets. Read more... More about Mashable Video, Health Care, Social G\u2026", "url": "https://mashable.com/video/nanette-cocero-social-good-summit/", "urlToImage": "https://i.amz.mshcdn.com/3WctZ_5TjrIFQicIEilXstntbtE=/1200x630/2018%2F10%2F01%2F3a%2Fc550f14ff7fb4b8fad7c30e3751c2c28.a955c.jpg", "publishedAt": "2018-10-01T14:05:24Z", "content": null}, {"source": {"id": "techcrunch", "name": "TechCrunch"}, "author": "Kate Clark", "title": "Indigo raises $250M, launches marketplace to help farmers get paid for quality grain", "description": "Indigo, the startup bringing algorithms and machine learning to the agricultural industry, has raised a $250 million Series E, bringing its total raised to $650 million. The funding values the company at $3.5 billion, according to a source familiar with the d\u2026", "url": "http://techcrunch.com/2018/09/18/indigo-raises-250m-launches-marketplace-to-help-farmers-get-paid-for-quality-grain/", "urlToImage": "https://techcrunch.com/wp-content/uploads/2018/09/Indigo_Wheat1.jpeg?w=600", "publishedAt": "2018-09-18T13:00:15Z", "content": "Indigo, the startup bringing algorithms and machine learning to the agricultural industry, has raised a $250 million Series E, bringing its total raised to $650 million. The funding values the company at $3.5 billion, according to a source familiar with the d\u2026 [+2449 chars]"}, {"source": {"id": "business-insider", "name": "Business Insider"}, "author": "Will Martin and Reuters", "title": "Pfizer's long-serving CEO Ian Read is standing down and being replaced by his chief operating officer (PFE)", "description": "Pfizer announces that CEO Ian Read will stand down from the start of 2019. He will be replaced by Dr. Albert Bourla, who is currently Pfizer's chief operating officer. \"It\u2019s been an honor to serve as Pfizer\u2019s CEO for the past eight years,\" Read said in a stat\u2026", "url": "https://www.businessinsider.com/pfizer-ceo-ian-read-to-step-down-2018-10", "urlToImage": "https://amp.businessinsider.com/images/570728d79105844d018bb665-2732-1366.jpg", "publishedAt": "2018-10-01T11:24:01Z", "content": "Ian Read, the long-serving chief executive officer of pharmaceutical giant Pfizer is set to step down, the company announced on Monday. Read, who has been at the helm of the firm since 2010, will stand down on January 1. He will be replaced by Dr. Albert Bour\u2026 [+922 chars]"}, {"source": {"id": "business-insider", "name": "Business Insider"}, "author": "Lydia Ramsey and Charlotte Hu", "title": "The Trump administration's top health official isn't counting on pharma to bring down drug prices", "description": "Health and Human Services Secretary Alex Azar isn't counting on pharmaceutical companies to do the right thing when it comes to drug prices. \"I'm not counting on their altruism or their cooperation,\" Azar said at the Financial Times' Pharma Pricing Summit on \u2026", "url": "https://www.businessinsider.com/hhs-secretary-alex-azar-on-drug-pricing-2018-9", "urlToImage": "https://amp.businessinsider.com/images/5a1ee1183dbef484008b8f22-2732-1366.jpg", "publishedAt": "2018-09-13T14:34:06Z", "content": "Department of Health and Human Services Secretary Alex Azar isn't banking on the pharmaceutical industry to fix the rising cost of prescription drugs in the US. \"I'm not counting on their altruism or their cooperation,\" Azar said at the Financial Times' Pharm\u2026 [+1364 chars]"}, {"source": {"id": "the-guardian-au", "name": "The Guardian (AU)"}, "author": "Hannah Summers", "title": "UK regulator certifies use of some out-of-date EpiPens over shortages", "description": "Four-month extension of use of expired EpiPens does not apply to Junior version Children with severe allergies who need to carry life-saving medication are being forced to rely on out-of-date EpiPens due to a global shortage of the adrenaline shots. EpiPen an\u2026", "url": "https://www.theguardian.com/society/2018/sep/29/uk-regulator-certifies-use-of-some-out-of-date-epipens-over-shortages", "urlToImage": "https://i.guim.co.uk/img/media/b09bb51fea55ac9654b3a8fcef422ccd4202f8b7/0_99_3467_2080/master/3467.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&crop=faces%2Centropy&bm=normal&ba=bottom%2Cleft&blend64=aHR0cHM6Ly9hc3NldHMuZ3VpbS5jby51ay9pbWFnZXMvb3ZlcmxheXMvZDM1ODZhNWVmNTc4MTc1NmQyMWEzYjYzNWU1MTcxNDEvdGctZGVmYXVsdC5wbmc&s=1d1d69302ab992d2d19c752a939a50b3", "publishedAt": "2018-09-29T12:00:42Z", "content": "Children with severe allergies who need to carry life-saving medication are being forced to rely on out-of-date EpiPens due to a global shortage of the adrenaline shots. EpiPen and EpiPen Junior devices, which are supplied by Mylan and produced by Pfizer, hav\u2026 [+3762 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "CEO of US drugs giant Pfizer stepping down", "description": "US drugmaker Pfizer on Monday announced that chief executive Ian Read is stepping down, handing off to chief operating officer Albert Bourla on January 1. Read will serve in future as executive chairman of Pfizer's board of directors, the company said in a st\u2026", "url": "https://www.yahoo.com/news/ceo-us-drugs-giant-pfizer-stepping-down-115424434.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/K7t7UT59FzWRoarjrWu4gg--~B/aD02ODE7dz0xMDI0O3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en_us/News/afp.com/Part-DV-DV1724164-1-1-1.jpg", "publishedAt": "2018-10-01T11:54:24Z", "content": "New York (AFP) - US drugmaker Pfizer on Monday announced that chief executive Ian Read is stepping down, handing off to chief operating officer Albert Bourla on January 1. Read will serve in future as executive chairman of Pfizer's board of directors, the com\u2026 [+1303 chars]"}, {"source": {"id": "techcrunch", "name": "TechCrunch"}, "author": "John Biggs", "title": "Meet the startups in the latest Alchemist class", "description": "Alchemist is the Valley\u2019s premiere enterprise accelerator and every season they feature a group of promising startups. They are also trying something new this year: they\u2019re putting a reserve button next to each company, allowing angels to express their intere\u2026", "url": "http://techcrunch.com/2018/09/20/meet-the-startups-in-the-latest-alchemist-class/", "urlToImage": "https://techcrunch.com/wp-content/uploads/2018/09/image151.png?w=653", "publishedAt": "2018-09-20T17:30:10Z", "content": "Alchemist is the Valley\u2019s premiere enterprise accelerator and every season they feature a group of promising startups. They are also trying something new this year: they\u2019re putting a reserve button next to each company, allowing angels to express their intere\u2026 [+10659 chars]"}, {"source": {"id": null, "name": "Phys.org"}, "author": null, "title": "Drugmaker Pfizer's CEO Read to leave in January", "description": "The biggest U.S.-based drugmaker will change leaders in January when Pfizer Chief Operating Officer Albert Bourla replaces CEO Ian Read, who has led the company for nearly eight years.", "url": "https://phys.org/news/2018-10-drugmaker-pfizer-ceo-january.html", "urlToImage": "https://3c1703fe8d.site.internapcdn.net/newman/gfx/news/2018/drugmakerpfi.jpg", "publishedAt": "2018-10-01T13:47:00Z", "content": "In this May 13, 2014, file photo, Pfizer CEO Ian Read arrives for a committee hearing at Portcullis House in London. The drugmaker Pfizer will replace Read with Chief Operating Officer Albert Bourla in January 2019. (AP Photo/Matt Dunham, File) The biggest U.\u2026 [+2411 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Better Buy: Novavax, Inc. vs. Pfizer Inc.", "description": "Which stock wins in a matchup between an up-and-coming biotech and a longtime big pharma winner?", "url": "https://www.fool.com/investing/2018/09/30/better-buy-novavax-inc-vs-pfizer-inc.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F495715%2Fpreparing-to-give-vaccine-shot.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-30T11:01:00Z", "content": "On paper, there's really no contest between Novavax, Inc. ( NASDAQ:NVAX ) and Pfizer Inc. ( NYSE:PFE ). Novavax has no approved products. It doesn't have a steady source of revenue. Pfizer, of course, has dozens of approved products and generates billions of \u2026 [+5095 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (George Budwell)", "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://www.fool.com/investing/2018/09/07/why-exact-sciences-corporation-stock-rocketed-high.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493775%2Frocketman.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences ( NASDAQ:EXAS ), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-\u2026 [+1929 chars]"}, {"source": {"id": null, "name": "Futurity.org"}, "author": "Mark Michaud-Rochester", "title": "Common painkiller doesn\u2019t ease chronic pain after injury", "description": "A common painkiller doesn't offer much relief for people who have suffered a traumatic nerve injury. But there is some good news.", "url": "https://www.futurity.org/chronic-pain-painkiller-nerve-injury-1873382-2/", "urlToImage": "https://www.futurity.org/wp/wp-content/uploads/2018/09/pills-on-yellow_1600.jpg", "publishedAt": "2018-09-25T16:20:17Z", "content": "A common painkiller isn\u2019t effective in controlling the chronic pain that sometimes develops following traumatic nerve injurybut shows promise in relieving pain that may linger after surgery, according to a new study. The FDA has approved pregabalin, which Pfi\u2026 [+4206 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://www.fool.com/investing/2018/09/06/3-top-big-pharma-stocks-to-buy-now.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493451%2Fpharmaceutical-research.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4543 chars]"}, {"source": {"id": "the-wall-street-journal", "name": "The Wall Street Journal"}, "author": "Jonathan D. Rockoff", "title": "Pfizer CEO Read to Step Aside at Year's End", "description": "Ian Read plans to step aside as Pfizer\u2019s chief executive after eight years helming one of the world\u2019s biggest drug makers.", "url": "https://www.wsj.com/articles/pfizer-ceo-read-to-step-aside-at-years-end-1538390220", "urlToImage": "https://images.wsj.net/im-28674/social", "publishedAt": "2018-10-01T10:49:42Z", "content": "Pfizer Inc.s PFE 0.39% Ian Read plans to step aside as chief executive after eight years helming one of the worlds biggest drugmakers, handing over the reins to deputy Albert Bourla, as the company seeks to boost sales in a tougher pricing and reimbursement c\u2026 [+6125 chars]"}, {"source": {"id": null, "name": "Entrepreneur.com"}, "author": "Isa Watson", "title": "Not Your Parents' Career Development", "description": "In today's world, professional success doesn't mean what it used to.", "url": "https://www.entrepreneur.com/article/319624", "urlToImage": "https://assets.entrepreneur.com/content/3x2/2000/20180919182539-GettyImages-661789569.jpeg", "publishedAt": "2018-09-20T13:30:00Z", "content": "September 20, 2018 6 min read Opinions expressed by Entrepreneur contributors are their own. For my parents, a career meant one thing: progressing through the ranks at a single company, climbing a corporate ladder where growth could be measured through regula\u2026 [+5785 chars]"}, {"source": {"id": "the-economist", "name": "The Economist"}, "author": null, "title": "Business this week", "description": "The Trump administration intensified its trade war with China, threatening to impose tariffs on a further $200bn-worth of goods, including tuna, chemicals and handbags.", "url": "https://www.economist.com/the-world-this-week/2018/07/12/business-this-week", "urlToImage": "/assets/the-economist-logo.png", "publishedAt": "2018-09-20T14:46:47Z", "content": "The Trump administration intensified its trade war with China, threatening to impose tariffs on a further $200bn-worth of goods, including tuna, chemicals and handbags. This came a few days after America fired its first salvo, levying duties on $34bn-worth of\u2026 [+4466 chars]"}, {"source": {"id": "bloomberg", "name": "Bloomberg"}, "author": null, "title": "Pfizer CEO's Transition Leaves Wall Street Divided on M&A Strategy", "description": null, "url": "https://www.bloomberg.com/tosv2.html?vid=&uuid=ab752b80-c592-11e8-8325-570d17bae62d&url=L25ld3MvYXJ0aWNsZXMvMjAxOC0xMC0wMS9wZml6ZXItY2VvLXRyYW5zaXRpb24tbGVhdmVzLXN0cmVldC1kaXZpZGVkLW9uLW0tYS1zdHJhdGVneQ==", "urlToImage": null, "publishedAt": "2018-10-01T15:11:06Z", "content": "Your usage has been flagged as a violation of our terms of service. For inquiries related to this message please contact support. For sales inquiries, please visit http://www.bloomberg.com/professional/request-demo If you believe this to be in error, please c\u2026 [+280 chars]"}, {"source": {"id": "the-economist", "name": "The Economist"}, "author": null, "title": "Business this week", "description": "The  IMF warned that the tariffs on imports threatened by both President Donald Trump and his trading partners could lower the annual growth rate of the global economy by 0.5 percentage points by 2020. The fund left its forecasts for global economic growth in\u2026", "url": "https://www.economist.com/the-world-this-week/2018/07/19/business-this-week", "urlToImage": "https://cdn.static-economist.com/sites/default/files/images/print-edition/20180721_WWP004_0.jpg", "publishedAt": "2018-09-20T14:46:47Z", "content": "The IMF warned that the tariffs on imports threatened by both President Donald Trump and his trading partners could lower the annual growth rate of the global economy by 0.5 percentage points by 2020. The fund left its forecasts for global economic growth in \u2026 [+4282 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "Deepak Patel", "title": "Oxytocin production by private companies: Delhi HC defers ban to November 1", "description": "The three petitioners in this case are Mylan Laboratories, Neon Laboratories and All India Drug Action Network (AIDAN). Pfizer and Mylan are two leading producers of Oxytocin in India.", "url": "https://indianexpress.com/article/business/companies/oxytocin-production-by-private-companies-delhi-hc-defers-ban-to-november-1-5378812/", "urlToImage": "https://images.indianexpress.com/2018/08/hammer-main1111.jpg?w=759", "publishedAt": "2018-09-28T22:26:49Z", "content": "Written by Deepak Patel | New Delhi | Published: September 29, 2018 3:56:49 am The Centre had issued a notification to implement the ban from September 1. However, the Centre clarified that private companies would be free to manufacture Oxytocin in India for \u2026 [+1792 chars]"}, {"source": {"id": "bloomberg", "name": "Bloomberg"}, "author": null, "title": "Pfizer to Idle Plants in North Carolina With Hurricane Florence Approaching", "description": null, "url": "https://www.bloomberg.com/tosv2.html?vid=&uuid=ec67c3a0-b5ed-11e8-a686-d35d83610e7e&url=L25ld3MvYXJ0aWNsZXMvMjAxOC0wOS0xMS9wZml6ZXItdG8taWRsZS1wbGFudHMtaW4tbm9ydGgtY2Fyb2xpbmEtYXMtaHVycmljYW5lLWFwcHJvYWNoZXM=", "urlToImage": null, "publishedAt": "2018-09-11T17:07:37Z", "content": "Your usage has been flagged as a violation of our terms of service. For inquiries related to this message please contact support. For sales inquiries, please visit http://www.bloomberg.com/professional/request-demo If you believe this to be in error, please c\u2026 [+280 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "REUTERS", "title": "Pfizer CEO Ian Read to step down next year", "description": "Read, who was appointed CEO in December 2010, will become the executive chairman of Pfizer's board from Jan. 1.", "url": "https://economictimes.indiatimes.com/news/international/pfizer-ceo-ian-read-to-step-down-next-year/articleshow/66029115.cms", "urlToImage": "https://img.etimg.com/thumb/msid-66029139,width-1070,height-580,imgsize-146480,overlay-economictimes/photo.jpg", "publishedAt": "2018-10-01T11:15:00Z", "content": "Drugmaker Pfizer Inc said on Monday Chief Executive Officer Ian Read would step down at the start of next year and would be replaced by Chief Operating Officer Albert Bourla. Read, who was appointed CEO in December 2010, will become the executive chairman of \u2026 [+769 chars]"}]}